Literature DB >> 1734081

Active cancer therapy combining 13-cis-retinoic acid with interferon-alpha.

E Dmitrovsky, G J Bosl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1734081     DOI： 10.1093/jnci/84.4.218

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

1.  Opposing cytokine-specific effects of all trans-retinoic acid on the activation and expression of signal transducer and activator of transcription (STAT)-1 in THP-1 cells.

Authors:  Qiuyan Chen; Yifan Ma; A Catharine Ross
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

2.  An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92.

Authors:  J H Schiller; D Neuberg; D Burns; P Ritch; M Larson; M Levitt; J Dutcher
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Unexpected radiation protection with 13-cis-retinoic acid plus interferon alpha-2a.

Authors:  K A Mason; P J Tofilon
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Interferon treatment of human malignancies--a short review.

Authors:  S Einhorn; H Strander
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

5.  Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer.

Authors:  N Voravud; S M Lippman; R S Weber; G I Rodriquez; D Yee; I W Dimery; C L Earley; D D Von Hoff; W K Hong
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

6.  Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.

Authors:  G Fierlbeck; T Schreiner; G Rassner
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.